Novavax Grows Presence at World Vaccine Congress and 32nd European Congress of Clinical Microbiology & Infectious Diseases

– New data on COVID-19 Influenza combination vaccine and seasonal influenza vaccine to be presented at World Vaccine Congress

– Several abstracts and presentations slated to highlight updates on NVX-CoV2373, Novavax’ COVID-19 vaccine

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, will provide a first look at data from its COVID-19 influenza combination vaccine and seasonal influenza vaccine trials, at the World Vaccine Congress [ https://c212.net/c/link/?t=0&l=en&o=3507542-1&h=1840594479&u=https%3A%2F%2Fwww.terrapinn.com%2Fconference%2Fworld-vaccine-congress-washington%2Findex.stm&a=World+Vaccine+Congress ] (WVC) in Washington, DC, April 18 – 21, 2022. In addition, the latest data on its protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be presented at both WVC and the 32nd European Congress of Clinical Microbiology & Infectious Diseases [ https://c212.net/c/link/?t=0&l=en&o=3507542-1&h=1505958255&u=https%3A%2F%2Fwww.eccmid.org%2F&a=32nd+European+Congress+of+Clinical+Microbiology+%26+Infectious+Diseases ] (ECCMID) in in Lisbon, Portugal, April 23 – 26, 2022. Data from eight abstracts and presentations, including four oral presentations, will be presented across the two congresses.

Gregory M. Glenn, M.D., President, Research and Development, Novavax, said: “Our presence at these two leading industry conferences shows our ongoing commitment to addressing COVID-19, and the advances we have made towards a next-generation influenza vaccine. We look forward to sharing these updates that further demonstrate the potential for our platform.”

Key Novavax presentations during WVC:

Glenn, G How long will our immunity Panel
against COVID-19 last for April 19, 2022
and will our vaccines 8:45 – 9:45 ET
continue to work against
VoCs?

Kim, D Monitoring COVID-19 Vaccine Panel
Safety under Emergency Use April 20, 2022
Authorization: Challenges 12:10 – 1:10 ET
and Lessons?

Glenn, G Clinical Update on Novavax’s Oral
Recombinant Nanoparticle Session COVID & Beyond – M4
Protein Subunit COVID-19 April 20, 2022
Vaccine as a Booster 12:40 – 1:00 ET

Shinde, V Update on Novavax’ NanoFlu* Oral
vaccine and COVID-19 Session Influenza and
-Influenza Combination Respiratory – M4
Vaccine development April 20, 2022
12:40 – 1:10 ET

*NanoFlu identifies a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine candidate produced by Novavax. This investigational candidate was evaluated during a controlled phase 3 trial conducted during the 2019-2020 influenza season.

Key Novavax presentations during ECCMID:

Toback, S Ongoing safety and efficacy Abstract #04525
of the NVX-CoV2373 COVID-19 Oral
vaccine in the United Kingdom Session Late breaking updates
on COVID vaccination
April 25, 2022
16:15 – 17:15 CET

Shinde, V Long-term durability of Abstract #1197
antigen-specific polyfunctional Oral
CD4+ T cell responses against Session Viral respiratory
vaccine-homologous and infections: Influenza and RSV
antigenically drifted April 26, 2022
viruses: results of a 11:00 – 12:00 CET
phase III trial of
a recombinant quadrivalent
hemagglutinin
saponin-adjuvanted nanoparticle
influenza

Anez, G Safety, efficacy and Abstract #04455
effectiveness of a Poster
SARS-CoV-2 adjuvanted Session 12g. Vaccine
recombinant spike protein development, trials,
vaccine (NVX-CoV2373) efficacy, policy
in a phase III trial April 25, 2022
in adolescents (PREVENT-19) 12:00 – 13:00 CET

Anez, G Molecular epidemiology of Abstract #00284
SARS-CoV-2 strains identified Poster
during a phase III, Session 12l. Virus
efficacy and safety trial of evolution, variants, and
NVX-CoV2373 vaccine impact
(PREVENT-19) in the United April 25, 2022
States and Mexico 12:00 – 13:00 CET

Beyhaghi, H Reported pregnancies and Abstract #01705
associated outcomes across Poster
the NVX-CoV2373 COVID-19 Session 12g. Vaccine
vaccine clinical development development, trials,
programme efficacy, policy
April 25, 2022
12:00 – 13:00 CET

Marchese, A COVID-19 vaccine receptivity Abstract #04362
and preferences among Poster
“vaccine hesitants” Session 12g. Vaccine
development, trials,
efficacy, policy
April 25, 2022
12:00 – 13:00 CET

For more information or to register, visit the World Vaccine Congress Washington 2022 [ https://c212.net/c/link/?t=0&l=en&o=3507542-1&h=3395465361&u=https%3A%2F%2Fwww.terrapinn.com%2Fconference%2Fworld-vaccine-congress-washington%2Findex.stm&a=World+Vaccine+Congress+Washington+2022 ] and the 32nd European Congress of Clinical Microbiology & Infectious Diseases [ https://c212.net/c/link/?t=0&l=en&o=3507542-1&h=1505958255&u=https%3A%2F%2Fwww.eccmid.org%2F&a=32nd+European+Congress+of+Clinical+Microbiology+%26+Infectious+Diseases ] websites.

About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company’s proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. NVX-CoV2373, the company’s COVID-19 vaccine, has received conditional authorization from multiple regulatory authorities globally, including the European Commission and the World Health Organization. The vaccine is also under review by multiple regulatory agencies worldwide. In addition to its COVID-19 vaccine, Novavax is also currently evaluating a COVID-seasonal influenza combination vaccine in a Phase 1/2 clinical trial, which combines NVX-CoV2373 and its quadrivalent influenza investigational vaccine candidate, previously referred to as NanoFlu. These vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M(TM) adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

For more information, visit www.novavax.com and connect with us on LinkedIn [ https://www.linkedin.com/company/novavax/ ] .

Contacts:
Investors
Erika Schultz | 240-268-2022
ir@novavax.com

Media
Ali Chartan | 240-720-7804
Laura Keenan Lindsey | 202-709-7521
media@novavax.com

SOURCE Novavax, Inc.

Logo – https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg